Number of Study Participants Sample Clauses

Number of Study Participants. There will be about 30 participants taking part in this study. Length of Study for Participants You will be in this study for about 45 days. This does not include the time between screening (the period during which your eligibility for participation in this study will be assessed) and dosing, which can be up to 28 days. This study involves:  4 dosing periods during one continuous admission  18 overnight stays at the Clinical Research Unit (CRU). You will not be able to leave the CRU during that time  1 follow-up phone call about 4 weeks after the last dose There will be at least 5 days between each dose. Eligibility to Participate in Another Drug Study Your eligibility to take part in another study depends on information from this study and the ongoing study. You may be eligible to receive a different study drug in another study as soon as 30 days after your last dose of study drug in this study. This is true for most drugs. Some drugs may stay in your body longer, which means that you may have to wait longer before joining another study. These results are usually known after your last blood sample is tested. We will tell you this as soon as possible. We will also tell you if there is a longer than usual period of time that you should not be in another drug study after this one. Our goal is to keep you from doing anything that might potentially harm you. Dosing Plan The dose of the study drug that will be used to treat people with cancer is not yet known. One group of participants is planned. Dosing in this study is planned as follows: Study Treatment A: 300 mg of study drug (two 125 mg and two 25 mg tablets) IR MST faster dissolution (faster dissolving), fasted (without food) Study Treatment B: 300 mg of study drug (two 125 mg and two 25 mg tablets) IR MST moderate dissolution, fasted Study Treatment C: 300 mg of study drug (four 75 mg tablets) IR DC batch moderate dissolution, fasted Study Treatment D: 300 mg of study drug (four 75 mg tablets) IR DC Continuous (slower dissolution), fasted Study Treatment E: 300 mg of study drug (four 75 mg tablets) IR DC Batch moderate dissolution, fed (with food) An IR (immediate release) formulation releases the active ingredients of a drug in a short period of time. MST (material sparing tablet) means that these tablets were developed on a small scale in order to keep the use of materials low. DC (direct compression) is a manufacturing process. Your study treatment sequence will be randomly assigned, like pulling a...
Sample 1See All (6)
AutoNDA by SimpleDocs
Number of Study Participants. There will be about 14 people taking part in this study. If possible, 4 of the people will be of Japanese descent. The safety of the study drug and the amount of the study drug in the blood in Japanese participants, if enrolled, will be compared to that of non-Japanese participants. Length of Study for Participants You will be in this study for up to about 29 days. This does not include the time between screening and dosing, which can be up to 28 days. This study involves: • 2 dosing periods with a single admission. The admission has 3 overnight stays at the Clinical research Unit (CRU). You will not be able to leave the CRU during that time • 1 follow-up phone call about 4 weeks after the last dose Eligibility to Participate in Another Drug Study Your eligibility to take part in another study depends on information from previous studies. You may be eligible to receive a different study drug in another study as early as 30 days after your last dose of study drug in this study. This is true for most drugs. Some drugs may stay in your body longer which means that you may have to wait longer before joining another study. These results are usually known after your last blood sample is tested. We will tell you this as soon as possible. We will also tell you if there is a longer than usual period of time that you should not be in another drug study after this one. Our goal is to keep you from doing anything that might potentially harm you. Dosing Plan The recommended dose of the study drug used to treat people is 10 mg. One group of 14 participants is planned. Participants will be split into two groups of 7 each. Dosing is planned as follows: STUDY GROUP NUMBER OF PARTICIPANTS STUDY PERIOD 1 2 STUDY TREATMENT MICROSAMPLING DEVICE STUDY TREATMENT
Sample 1
Number of Study Participants. PART A There will be up to 32 people joining this part of the study.
Sample 1Sample 2
Number of Study Participants. This study is being done at about 2 different study sites in 2 countries. There will be up to 12 participants in this part of the study. Length of Study for Participants You will be in this study for up to about 51 days. This does not include the time between screening and dosing, which can be up to 28 days. This study involves:  Up to 4 dosing periods (Periods 3 and 4 are optional) during a continuous admission  Up to 20 overnight stays at the Clinical Research Unit (CRU). You will not be able to leave the CRU during that time  1 follow-up phone call about 4 weeks after the last dose of study drug Eligibility to Participate in Another Drug Study Your eligibility to take part in another study depends on information from this study. You may be eligible to receive a different study drug in another study as soon as 30 days after your last dose of study drug in this study. This is true for most drugs. Some drugs may stay in your body longer which means that you may have to wait longer before joining another study. These results are usually known after your last blood sample is tested. We will tell you this as soon as possible. We will also tell you if there is a longer than usual period of time that you should not be in another drug study after this one. Our goal is to keep you from doing anything that might potentially harm you. Dosing Plan The dose of the study drug that will be used to treat COVID patients is not yet known. One group of up to 12 participants will be in this part of the study. The total daily dose level of study drug in this cohort will not exceed 3,000 mg. Dosing is planned as follows: Dosing Sequence Number of Participants Dosing Periods
Sample 1
Number of Study Participants. [NUMBER OF PARTICIPANTS] Description Frequency/details Per Unit Total for all participants Per Study Participant fee Additional Assessments Screen Failures Unscheduled visits Subject Travel reimbursement Pharmacy Cost Start-up fee Archiving fee Audit fee
Sample 1
Number of Study Participants. There will be about 42 people taking part in this study. Length of Study for Participants You will be in this study for up to about 50 days. This does not include the time between screening and dosing, which can be up to 28 days. This study involves: • 3 dosing periods during 1 continuous admission • 22 overnight stays at the CRU. You will not be able to leave the CRU during that time • 1 follow-up phone call about 4 weeks after the last dose There will be at least 7 days between the last dose in one period and the first dose in the next period Eligibility to Participate in Another Drug Study Your eligibility to take part in another study depends on information from the previous study and this study. You may be eligible to receive a different study drug in another study as early as 30 days after your last dose of study drug in this study. This is true for most drugs. Some drugs may stay in your body longer which means that you may have to wait longer before joining another study. These results are usually known after your last blood sample is tested. We will tell you this as soon as possible. We will also tell you if there is a longer than usual period of time that you should not be in another drug study after this one. Our goal is to keep you from doing anything that might potentially harm you. Dosing Plan The dose of the study drug that will be used to treat people is not yet known. One group of 42 participants is planned. Dosing is planned as follows: DOSING SEQUENCE NUMBER OF PARTICIPANTS STUDY PERIOD
Sample 1
Number of Study Participants. There will be about 53 participants taking part in this part of the study. This study is being done at about 4 different study sites in 2 countries. It is expected that about 11 people will take part in this part of the study at this location. This research study may use competitive enrollment. This means that when a certain number of people have entered the research study from all research sites combined, no one else will be allowed to participate. It is possible that you may not be allowed to join the research study.
Sample 1
AutoNDA by SimpleDocs
Number of Study Participants. This study is being done at about 2 different study sites in 2 countries. There will be up to 60 people in the study, 12 participants in Part 1, up to 30 participants in Part 2 (including 6 Japanese participants if the optional Japanese group is conducted) and a maximum of 18 participants in Part 3 (if done).
Sample 1
Number of Study Participants. 183 Statistical Methods
Sample 1

Related to Number of Study Participants

  • Number of Stewards The Union may designate one (1), but no more than one (1), xxxxxxx on each shift for each of the Employer's principal work areas from among those employees who work therein.

  • Number of Units The Participant is granted the number of RSUs as specified in the Participant’s account under the 0000 XXX grant, administered by Fidelity Investments or any successor thereto (“Fidelity”). A RSU is a hypothetical share of Verizon’s common stock. The value of a RSU on any given date shall be equal to the closing price of Verizon’s common stock on the New York Stock Exchange (“NYSE”) as of such date. A Dividend Equivalent Unit (“DEU”) or fraction thereof shall be added to each RSU each time that a dividend is paid on Verizon’s common stock. The amount of each DEU shall be equal to the corresponding dividend paid on a share of Verizon’s common stock. The DEU shall be converted into RSUs or fractions thereof based upon the closing price of Verizon’s common stock traded on the NYSE on the dividend payment date of each declared dividend on Verizon’s common stock, and such RSUs or fractions thereof shall be added to the Participant’s RSU balance. To the extent that Fidelity or the Company makes an error, including but not limited to an administrative error with respect to the number or value of the RSUs granted to the Participant under this Agreement, the DEUs credited to the Participant’s account or the amount of the final award payment, the Company or Fidelity specifically reserves the right to correct such error at any time and the Participant agrees that he or she shall be legally bound by any corrective action taken by the Company or Fidelity.

  • Salary Progression 1. For the purposes of determining annual progression from one step to the next, each teacher’s performance will be assessed annually against the appropriate professional standards.

  • Initial Enrollment Upon retirement, each new retiree who is eligible to enroll in plans under the Health Benefits Program shall receive uninterrupted coverage under the plan in which he or she was enrolled as an active employee, provided the employee submits all necessary applications and other required documentation in a timely fashion.

  • Estimated Number of Participating Households Approximately 6,460. This figure is based on loans with unpaid principal balances ranging from $200,000 to $400,000 with an average funding of $5,000.00.

  • Evaluation Cycle Goal Setting and Development of the Educator Plan

  • Number of Employees The Union and the Employer agree that no more than one (1) position in each program shall be covered by a Job Sharing Agreement at any one time. No more than two (2) employees may share one (1) full-time position. The position being shared shall remain a regular full-time position within the bargaining unit.

  • Number of Shares This Warrant shall be exercisable for the Initial Shares, plus the Additional Shares, if any (collectively, and as may be adjusted from time to time pursuant to the provisions of this Warrant, the “Shares”).

  • Special Enrollment Under the circumstances described below, referred to as “qualifying events”, eligible employees and/or eligible dependents may request to enroll in the Plan outside of the initial and annual open enrollment periods, during a special enrollment period.

  • Salary Review All salaries below the maximum of a band shall be reviewed annually.

Time is Money Join Law Insider Premium to draft better contracts faster.